itk 7

PARP11 Inhibitor ITK7 (ITK7) is a potent, selective inhibitor of PARP11, demonstrating significant efficacy with an IC50 value of 14 nM. It is primarily utilized in research focused on cellular localization.

BMS-986143, an orally active, reversible BTK inhibitor with an IC50 value of 0.26 nM, is designed for autoimmune disease research. Additionally, it targets TEC, BLK, BMX, TXK, FGR, YES1, and ITK, exhibiting IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM, 19 nM, and 21 nM, respectively [1].

BTK-IN-7 is a selective and potent BTK inhibitor with an IC50 value of 4.0 nM. BTK-IN-7 exhibits high selectivity at both the enzymatic (ITK>250-fold, EGFR>2500-fold) and cellular levels (ITK>227-fold, EGFR27-fold). BTK-IN-7 exhibits high high antitumor effect.